Breaking News Instant updates and real-time market news.

BIIB

Biogen

$294.07

-8.7 (-2.87%)

, FWP

Forward Pharma

$22.13

0.18 (0.82%)

12:47
12/01/16
12/01
12:47
12/01/16
12:47

Biogen's Tecfidera patent feud may pose risk, WSJ says

Biogen (BIIB) faced oral arguments this week in a patent interference hearing brought by a small Danish biotech company, Forward Pharma (FWP), regarding "its best-selling multiple sclerosis drug, Tecfidera," says the Wall Street Journal. With analysts expecting Biogen to book almost $4B in Tecfidera sales this year, representing more than a third of total sales for the drug giant, a win by Forward Pharma would impact Biogen, added the WSJ. Also according to the report, sales of Biogen's other best selling drugs Avonex and Tysabri are slowing. Reference Link

BIIB

Biogen

$294.07

-8.7 (-2.87%)

FWP

Forward Pharma

$22.13

0.18 (0.82%)

  • 07

    Dec

BIIB Biogen
$294.07

-8.7 (-2.87%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
11/23/16
MSCO
11/23/16
NO CHANGE
MSCO
Overweight
Morgan Stanley expects big reversal today in Biogen shares
Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.
FWP Forward Pharma
$22.13

0.18 (0.82%)

03/11/16
LEER
03/11/16
NO CHANGE
LEER
Outperform
Europe revoked Biogen's Tecfidera dosing patent, says Leerink
Leerink analyst Jason Gerberry points out that the European Patent Office yesterday revoked Biogen's (BIIB) Tecfidera dosing patent. The '537 patent in Europe is equivalent to the U.S. '514 patent subject to an ongoing patent interference versus Forward Pharma (FWP), Gerberry tells investors in a research note. The European Patent Office's detailed opinion explaining the rationale for the revocation has not yet published and may not be available for about a month, the analyst points out. He believes Europe's decision has "zero read-through" to the U.S. patent dispute between Forward and Biogen. Gerberry has an Outperform rating on Forward Pharma.
03/14/16
JMPS
03/14/16
NO CHANGE
JMPS
Forward Pharma has positive read through from patent ruling, says JMP Securities
After Biogen's (BIIB) '537 EU patent was revoked, JMP Securities thinks the news is positive for Forward Pharma (FWP). According to the firm, Forward now has the only patent in Europe for a 480 mg Dimethyl fumarate drug for the treatment of MS. The firm keeps a $33 price target and Outperform rating on Forward.
04/11/16
SBSH
04/11/16
NO CHANGE
Target $345
SBSH
Buy
Citi calls potential Biogen hemophilia sale 'surprising and confusing'
Citi analyst Robyn Karnauskas admits being "surprised and confused" after Reuters reported Friday that Biogen (BIIB) is exploring a sale of its hemophilia business. The analyst estimates the business is worth $4.8B-$6.4B. Biogen could use the cash to acquire a bigger strategic asset and/or buybacks, or may be trying to make itself "lean and more attractive as a potential M&A target," Karnauskas tells investors in a research note. She believes, however, that a takeout of Biogen "may be hard" given the uncertainty related to the Forward Pharma (FWP) patent issue regarding Tecfidera. Since the hemophilia business is growing at a time when peers in the sector are looking to diversify, investors will likely be confused should the unit be sold, Karnauskas writes. She keeps a Buy rating on Biogen.
08/03/16
JMPS
08/03/16
NO CHANGE
JMPS
Forward has positive read through from Biogen speculation, says JMP Securities
JMP Securities analyst Jason Butler thinks that acquisition speculation regarding Biogen (BIIB) highlights "underappreciated value" in Forward Pharma's IP portfolio. He continues to believe that Forward is undervalued, and he keeps a $33 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

MDR

McDermott

$7.13

0.3 (4.39%)

, MDSO

Medidata

$79.90

-0.35 (-0.44%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Breaking Hot Stocks news story on McDermott, Medidata »

McDermott to replace…

MDR

McDermott

$7.13

0.3 (4.39%)

MDSO

Medidata

$79.90

-0.35 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

BASFY

BASF

$95.05

-0.18 (-0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BOBE

Bob Evans

$72.53

0.24 (0.33%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Bob Evans management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

May Chicago Fed National…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

, PVTB

PrivateBancorp

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Medidata to replace PrivateBancorp in S&P 400 at open on 6/26 »

Canadian Imperial Bank of…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

PVTB

PrivateBancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MFG

Mizuho Financial Group

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Mizuho Financial Group management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

LULU

lululemon

$55.37

1.12 (2.06%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
lululemon management to meet with Barclays »

Meeting with CEO Laurent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AYR

Aircastle

$21.17

0.04 (0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

EXLS

ExlService

$55.05

0.15 (0.27%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
ExlService management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NBIX

Neurocrine

$47.35

0.23 (0.49%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

XOXO

XO Group

$17.60

0.1 (0.57%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
XO Group management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

May Durable Goods Orders…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools and…

SAVE

Spirit Airlines

$52.55

0.02 (0.04%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Spirit Airlines management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

May Durable Goods Orders…

04:40
06/26/17
06/26
04:40
06/26/17
04:40
General news
FX Action: The yen is under the cosh »

FX Action: The yen is…

03:10
06/26/17
06/26
03:10
06/26/17
03:10
General news
FX Update: The dollar has traded steady-to-softer »

FX Update: The dollar has…

03:05
06/26/17
06/26
03:05
06/26/17
03:05
General news
FX Action: USD-CAD is softer today »

FX Action: USD-CAD is…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.